Therapeutic options for 5-lipoxygenase inhibitors

Pharmacology and Therapeutics

Volumn 112, Issue 3, 2006, Pages 701-718

  Werz, Oliver ^a   Steinhilber, Dieter ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

5 Lipoxygenase; Arachidonic acid; Cancer; Cardiovascular disease; Inflammation; Leukotrienes

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 1 ETHYL 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 2 QUINOLONE; 2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY] PHENOXY]BENZOIC ACID; 2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 2 [4 [2 (4 CHLOROPHENYLTHIO)ETHOXY] 5 (3 HYDROXY 3 METHYLUREIDOMETHYL) 3 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 2,3,5 TRIMETHYL 6 (3 PYRIDYLMETHYL) 1,4 BENZOQUINONE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 5 HYDROPEROXY 6,8,11,14 ICOSATETRAENOIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; 7 CHLORO 4 HYDROXY 2 (4 METHOXYBENZYL) 3 METHYL 5 PROPYLBENZOFURAN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONIC ACID; ATRELEUTON; CMI 977; DG 031; DOCEBENONE; GEMCITABINE; GLUCOCORTICOID; LDP 977; LEUKOTRIENE A4; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LICOFELONE; LINAZOLAST; LIPOXYGENASE INHIBITOR; MONTELUKAST; R 68151; R 85355; UCB 35440; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

AIRWAY; ALLERGIC ASTHMA; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL WALL; CANCER; CARDIOVASCULAR DISEASE; CATALYSIS; CELL ADHESION; CHRONIC URTICARIA; CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG SAFETY; ENTERITIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EOSINOPHIL; FATTY ACID SYNTHESIS; HUMAN; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; MONOCYTE; MUCUS SECRETION; NEUTROPHIL; NONHUMAN; OBESITY; OSTEOPOROSIS; PANCREAS CANCER; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SKIN INFLAMMATION; ULCERATIVE COLITIS;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; LIPOXYGENASE INHIBITORS;

EID: 33750102847     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.05.009     Document Type: Review

References (213)

1. Abramovitz M., Wong E., Cox M.E., Richardson C.D., Li C., and Vickers P.J. 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 215 (1993) 105-111
2. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Freeman A., and Showell H.J. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22 (2002) 443-449
3. Albert D., Zundorf I., Dingermann T., Muller W.E., Steinhilber D., and Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 64 (2002) 1767-1775
4. Albert D., Bürkert E., Steinhilber D., and Werz O. Induction of 5-lipoxygenase activation in polymorphonuclear leukocytes by 1-oleoyl-2-acetylglycerol. Biochim Biophys Acta 1631 (2003) 85-93
5. Allen S.P., Dashwood M.R., Chester A.H., Tadjkarimi S., Collins M., Piper P.J., et al. Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4. Cardioscience 4 (1993) 47-54
6. Allen S., Dashwood M., Morrison K., and Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97 (1998) 2406-2413
7. Anderson K.M., Seed T., Vos M., Mulshine J., Meng J., Alrefai W., et al. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 37 (1998) 161-173
8. Anderson K.M., Alrefai W.A., Bonomi P.A., Anderson C.A., Dudeja P., and Harris J.E. A genomic response of H-358 bronchiolar carcinoma cells to MK 886, an inhibitor of 5-lipoxygenase, assessed with a cDNA array. Anticancer Res 20 (2000) 2433-2439
9. Anderson G.I., MacQuarrie R., Osinga C., Chen Y.F., Langman M., and Gilbert R. Inhibition of leukotriene function can modulate particulate-induced changes in bone cell differentiation and activity. J Biomed Mater Res 58 (2001) 406-414
10. Avis I.M., Jett M., Boyle T., Vos M.D., Moody T., Treston A.M., et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 97 (1996) 806-813
11. Avis I., Hong S.H., Martinez A., Moody T., Choi Y.H., Trepel J., et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 15 (2001) 2007-2009
12. Avis I., Martinez A., Tauler J., Zudaire E., Mayburd A., Abu-Ghazaleh R., et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 65 (2005) 4181-4190
13. Bell R.L., Young P.R., Albert D., Lanni C., Summers J.B., Brooks D.W., et al. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 14 (1992) 505-510
14. Boado R.J., Pardridge W.M., Vinters H.V., and Black K.L. Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. Proc Natl Acad Sci U S A 89 (1992) 9044-9048
15. Bonewald L.F., Flynn M., Qiao M., Dallas M.R., Mundy G.R., and Boyce B.F. Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv Exp Med Biol 433 (1997) 299-302
16. Bortuzzo C., Hanif R., Kashfi K., Staiano-Coico L., Shiff S.J., and Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1300 (1996) 240-246
17. Brain S.D., Camp R.D.R., Cunningham F.M., Dowd P.M., Greaves M.W., and Kobza-Black A. Leukotriene B4 like material in scale of psoriatic skin lesions. Br J Pharmacol 83 (1984) 313-317
18. 4 in psoriatic skin lesions. Prostaglandins 29 (1985) 611-619
19. Brideau C., Chan C., Charleson S., Denis D., Evans J.F., Ford-Hutchinson A.W., et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2 -yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 70 (1992) 799-807
20. Brink C., Dahlen S.E., Drazen J., Evans J.F., Hay D.W., Nicosia S., et al. International Union of Pharmacology: XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 55 (2003) 195-227
21. Brink C., Dahlen S.E., Drazen J., Evans J.F., Hay D.W., Rovati G.E., et al. International Union of Pharmacology: XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol Rev 56 (2004) 149-157
22. Brooks C.D.W., Stewart A.O., Basha A., Bhatia P., Ratajczyk J.D., Martin J.G., et al. R-(+)-N-[3-[5-(4-Fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N- hydroxyurea (ABT-761), a second generation 5-lipoxygenase inhibitor. J Med Chem 38 (1995) 4768-4775
23. 2+-dependent resistance of 5-lipoxygenase activity against inhibition by glutathione peroxidase-1. J Biol Chem 278 (2003) 42846-42853
24. Byrum R.S., Goulet J.L., Griffiths R.J., and Koller B.H. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 185 (1997) 1065-1075
25. Cai X., Scannell R.T., Yaeger D., Hussoin M.S., Killian D.B., Qian C., et al. (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N-hydr oxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. J Med Chem 41 (1998) 1970-1979
26. Carter G.W., Young P.R., Albert D.H., Bouska J., Dyer R., Bell R.L., et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256 (1991) 929-937
27. Catalano A., Caprari P., Soddu S., Procopio A., and Romano M. 5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking. FASEB J 18 (2004) 1740-1742
28. Catalano A., Rodilossi S., Caprari P., Coppola V., and Procopio A. 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO J 24 (2005) 170-179
29. Channon J.Y., and Leslie C.C. A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. J Biol Chem 265 (1990) 5409-5413
30. Chen X.S., and Funk C.D. The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation. J Biol Chem 276 (2001) 811-818
31. Chen X., Li N., Wang S., Wu N., Hong J., Jiao X., et al. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Natl Cancer Inst 95 (2003) 1053-1061
32. Chen X., Wang S., Wu N., and Yang C.S. Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr Cancer Drug Targets 4 (2004) 267-283
33. Claesson H.E., and Dahlen S.E. Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J Intern Med 245 (1999) 205-227
34. Claria J., Lee M.H., and Serhan C.N. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 2 (1996) 583-596
35. Crawley G.C., Dowell R.I., Edwards P.N., Foster S.J., McMillan R.M., Walker E.R., et al. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J Med Chem 35 (1992) 2600-2609
36. Dahlén S.E., Björk J., Hedqvist P., Arfors K.-E., Hammarström S., Lindgren J.Å., et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A 78 (1981) 3887-3891
37. Dahlén S.E., Hansson G., Hedqvist P., Björck T., Granström E., and Dahlén B. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4 and E4. Proc Natl Acad Sci U S A 80 (1983) 1712-1716
38. Davidson E.M., Rae S.A., and Smith M.J.H. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis 42 (1983) 677-679
39. De Caterina R., Mazzone A., Giannessi D., Sicari R., Pelosi W., Lazzerini G., et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta 47 (1988) S182-S185
40. Degreef H., Dockx P., De Doncker P., De Beule K., and Cauwenbergh G. A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor. J Am Acad Dermatol 22 (1990) 751-755
41. Ding X.Z., Iversen P., Cluck M.W., Knezetic J.A., and Adrian T.E. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 261 (1999) 218-223
42. Ding X.Z., Tong W.G., and Adrian T.E. Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer. Oncology 65 (2003) 285-294
43. Ding X.Z., Talamonti M.S., Bell Jr. R.H., and Adrian T.E. A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs 16 (2005) 467-473
44. Dixon R.A.F., Diehl R.E., Opas E., Rands E., Vickers P.J., Evans J.F., et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 (1990) 282-284
45. Drazen J.M., Yandava C.N., Dubé L., Szczerback N., Hippensteel R., Pillari A., et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22 (1999) 168-170
46. Ducharme Y., Brideau C., Dube D., Chan C.C., Falgueyret J.P., Gillard J.W., et al. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids. J Med Chem 37 (1994) 512-518
47. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
48. el-Hakim I.E., Langdon J.D., Zakrzewski J.T., and Costello J.F. Leukotriene B4 and oral cancer. Br J Oral Maxillofac Surg 28 (1990) 155-159
49. Fan X.M., Tu S.P., Lam S.K., Wang W.P., Wu J., Wong W.M., et al. 5-Lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax. J Gastroenterol Hepatol 19 (2004) 31-37
50. Feldberg W., and Kellaway C.H. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 94 (1938) 187-226
51. Ferry D.R., Deakin M., Baddeley J., Daryanani S., Bramhall S., Anderson D.A., et al. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann Oncol 11 (2000) 1165-1170
52. Feuerstein G. Leukotrienes and the cardiovascular system. Prostaglandins 27 (1984) 781-802
53. Fierro I.M., Kutok J.L., and Serhan C.N. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 300 (2002) 385-392
54. Fischer L., Szellas D., Rådmark O., Steinhilber D., and Werz O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J 17 (2003) 949-951
55. Flamand N., Surette M.E., Picard S., Bourgoin S., and Borgeat P. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol 62 (2002) 250-256
56. Flynn M.A., Qiao M., Garcia C., Dallas M., and Bonewald L.F. Avian osteoclast cells are stimulated to resorb calcified matrices by and possess receptors for leukotriene B4. Calcif Tissue Int 64 (1999) 154-159
57. Ford-Hutchinson A.W. 5-Lipoxygenase activation in psoriasis: a dead issue?. Skin Pharmacol 6 (1993) 292-297
58. Ford-Hutchinson A.W., Gresser M., and Young R.N. 5-Lipoxygenase. Annu Rev Biochem 63 (1994) 383-417
59. Franchi-Miller C., and Saffar J.L. The 5-lipoxygenase inhibitor BWA4C impairs osteoclastic resorption in a synchronized model of bone remodeling. Bone 17 (1995) 185-191
60. Fruchtmann R., Mohrs K.H., Hatzelmann A., Raddatz S., Fugmann B., Junge B., et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions 38 (1993) 188-195
61. Funk C.D. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1304 (1996) 65-84
62. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
63. Gallwitz W.E., Mundy G.R., Lee C.H., Qiao M., Roodman G.D., Raftery M., et al. 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. J Biol Chem 268 (1993) 10087-10094
64. Garcia C., Boyce B.F., Gilles J., Dallas M., Qiao M., Mundy G.R., et al. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res 11 (1996) 1619-1627
65. Garcia C., Qiao M., Chen D., Kirchen M., Gallwitz W., Mundy G.R., et al. Effects of synthetic peptido-leukotrienes on bone resorption in vitro. J Bone Miner Res 11 (1996) 521-529
66. Ghosh J. Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun 307 (2003) 342-349
67. Ghosh J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 315 (2004) 624-635
68. Ghosh J., and Myers C.E. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 235 (1997) 418-423
69. Ghosh J., and Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 95 (1998) 13182-13187
70. Giannaras A., Selig W., Ellis J., and Hullinger T. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol 506 (2005) 265-271
71. Goldman D.W., and Goetzl E.J. Heterogeneity of human polymorphonuclear leukocyte receptors for leukotriene B4. Identification of a subset of high affinity receptors that transduce the chemotactic response. J Exp Med 159 (1984) 1027-1041
72. Goppelt-Struebe M. Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. Biochem Pharmacol 53 (1997) 1389-1395
73. Griffiths R.J., Smith M.A., Roach M.L., Stock J.L., Stam E.J., Milici A.J., et al. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J Exp Med 185 (1997) 1123-1129
74. Gupta S., Srivastava M., Ahmad N., Sakamoto K., Bostwick D.G., and Mukhtar H. 5-Lipoxygenase is overexpressed in prostate adenocarcinoma. Cancer 91 (2001) 737-743
75. 4 biosynthesis. J Biol Chem 279 (2004) 50639-50642
76. Hakonarson H., Thorvaldsson S., Helgadottir A., Gudbjartsson D., Zink F., Andresdottir M., et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.[see comment]. JAMA 293 (2005) 2245-2256
77. Hamel P., Riendeau D., Brideau C., Chan C.C., Desmarais S., Delorme D., et al. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010. J Med Chem 40 (1997) 2866-2875
78. Hanaka H., Shimizu T., and Izumi T. Stress-induced nuclear export of 5-lipoxygenase. Biochem Biophys Res Commun 338 (2005) 111-116
79. Haribabu B., Verghese M.W., Steeber D.A., Sellars D.D., Bock C.B., and Snyderman R. Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 192 (2000) 433-438
80. Hawkey C.J., Dube L.M., Rountree L.V., Linnen P.J., and Lancaster J.F. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology 112 (1997) 718-724
81. Haynes Jr. J., Baliga B.S., Obiako B., Ofori-Acquah S., and Pace B. Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the l-arginine-nitric oxide signaling pathway. Blood 103 (2004) 3945-3950
82. Helgadottir A., Manolescu A., Thorleifsson G., Gretarsdottir S., Jonsdottir H., Thorsteinsdottir U., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
83. Helgadottir A., Gretarsdottir S., St. Clair D., Manolescu A., Cheung J., Thorleifsson G., et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 76 (2005) 505-509
84. Helgadottir A., Manolescu A., Helgason A., Thorleifsson G., Thorsteinsdottir U., Gudbjartsson D.F., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38 (2006) 68-74
85. Hennig R., Ding X.Z., Tong W.G., Schneider M.B., Standop J., Friess H., et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 161 (2002) 421-428
86. Hennig R.D., Ding X.Z., Tong W.G., Yokomizo T., Buchler M.W., Freiss H., et al. The leukotriene B4 receptor BLT2R is overexpressed in pancreatic intraepithelial neoplastic lesion (PanINS): a new target for therapy?. Pancreas 29 (2004) 336
87. Hennig R., Grippo P., Ding X.Z., Rao S.M., Buchler M.W., Friess H., et al. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res 65 (2005) 6011-6016
88. Hill E., Maclouf J., Murphy R.C., and Henson P.M. Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity. J Biol Chem 267 (1992) 22048-22053
89. Hong S.H., Avis I., Vos M.D., Martinez A., Treston A.M., and Mulshine J.L. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 59 (1999) 2223-2228
90. Hoque A., Lippman S.M., Wu T.T., Xu Y., Liang Z.D., Swisher S., et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 26 (2005) 785-791
91. Hörnig C., Albert D., Fischer L., Hörnig M., Rådmark O., Steinhilber D., et al. 1-Oleoyl-2-acetylglycerol stimulates 5-lipoxygenase activity via a putative (phospho)lipid binding site within the N-terminal C2-like domain. J Biol Chem 280 (2005) 26913-26921
92. Hosoi T., Koguchi Y., Sugikawa E., Chikada A., Ogawa K., Tsuda N., et al. Identification of a novel human eicosanoid receptor coupled to G(i/o). J Biol Chem 277 (2002) 31459-31465
93. In K.H., Asano K., Beier D., Grobholz J., Finn P.W., Silverman E.K., et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99 (1997) 1130-1137
94. Irvin C.G., Tu Y.P., Sheller J.R., and Funk C.D. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 16 (1997) L1053-L1058
95. Ishii K., Yakuo I., Seto Y., Kita A., Nakamura H., and Nishikawa Y. Antiallergic activity and mode of action of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3- pyridyl)acrylamide in experimental animals. Arzneimittelforschung 43 (1993) 148-154
96. 4 hydrolase. J Invest Dermatol 100 (1993) 293-298
97. Jakobsson P.J., Shaskin P., Larsson P., Feltenmark S., Odlander B., Aguilar-Santelises M., et al. Studies on the regulation and localization of 5-lipoxygenase in human B-lymphocytes. Eur J Biochem 232 (1995) 37-46
98. Jakobsson P.J., Morgenstern R., Mancini J., Ford-Hutchinson A., and Persson B. Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. Am J Respir Crit Care Med 161 (2000) S20-S24
99. Janssen-Timmen U., Vickers P.J., Wittig U., Lehmann W.D., Stark H.J., Fusenig N.E., et al. Expression of 5-lipoxygenase in differentiating human skin keratinocytes. Proc Natl Acad Sci U S A 92 (1995) 6966-6970
100. Jiang J., Lv H.S., Lin J.H., Jiang D.F., and Chen Z.K. LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. Artif Cells Blood Substitutes Immobilization Biotechnol 33 (2005) 391-403
101. Jiang W.G., Douglas-Jones A.G., and Mansel R.E. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival signifiance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 74 (2005) 125-134
102. Jones C.E., Holden S., Tenaillon L., Bhatia U., Seuwen K., Tranter P., et al. Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. Mol Pharmacol 63 (2003) 471-477
103. Kaaman M., Ryden M., Axelsson T., Nordstrom E., Sicard A., Bouloumie A., et al. ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance. Int J Obes 30 (2005) 447-452
104. Kanaoka Y., and Boyce J.A. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 173 (2004) 1503-1510
105. Kemp J.P. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med 2 (2003) 139-156
106. Kennedy T.J., Chan C.Y., Ding X.Z., and Adrian T.E. Lipoxygenase inhibitors for the treatment of pancreatic cancer. Expert Rev Anticancer Ther 3 (2003) 525-536
107. Klickstein L.B., Shapleigh C., and Goetzl E.J. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest 66 (1980) 1166-1170
108. Kulkarni S., Das S., Funk C.D., Murray D., and Cho W. Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase. J Biol Chem 277 (2002) 13167-13174
109. 4. Proc Natl Acad Sci U S A 91 (1994) 7663-7667
110. Laufer S., Tries S., Augustin J., and Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Drug Res 44 (1994) 629-636
111. Laviolette M., Malmström K., Lu S., Chervinsky P., Pujet J.C., Peszek I., et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 160 (1999) 1862-1868
112. Lehnigk B., Rabe K.F., Dent G., Herst R.S., Carpentier P.J., and Magnussen H. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J 11 (1998) 617-623
113. Letts L.G. Leukotrienes: role in cardiovascular physiology. Cardiovasc Clin 18 (1987) 101-113
114. Leung T.F., Li C.Y., Lam C.W., Au C.S., Yung E., Chan I.H., et al. The relation between obesity and asthmatic airway inflammation. Pediatr Allergy Immunol 15 (2004) 344-350
115. Lewis R.A., Austen K.F., and Soberman R.J. Leukotrienes and other products of the 5-lipoxygenase pathway-biochemistry and relation to pathobiology in human diseases. N Engl J Med 323 (1990) 645-655
116. Lewis T.A., Bayless L., Eckman J.B., Ellis J.L., Grewal G., Libertine L., et al. 5-Lipoxygenase inhibitors with histamine H(1) receptor antagonist activity. Bioorg Med Chem Lett 14 (2004) 2265-2268
117. Lewis T.A., Bayless L., Dipesa A.J., Eckman J.B., Gillard M., Libertine L., et al. 5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds. Bioorg Med Chem Lett 15 (2005) 1083-1085
118. Li N., Sood S., Wang S., Fang M., Wang P., Sun Z., et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 11 (2005) 2089-2096
119. Lobos E.A., Sharon P., and Stenson W.F. Chemotactic activity in inflammatory bowel disease: role of leukotriene B4. Dig Dis Sci 32 (1987) 1380-1388
120. Lohmussaar E., Gschwendtner A., Mueller J.C., Org T., Wichmann E., Hamann G., et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36 (2005) 731-736
121. Lotzer K., Spanbroek R., Hildner M., Urbach A., Heller R., Bretschneider E., et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 23 (2003) e32-e36
122. Luo M., Jones S.M., Peters-Golden M., and Brock T.G. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proc Natl Acad Sci U S A 100 (2003) 12165-12170
123. Luo M., Jones S.M., Phare S.M., Coffey M.J., Peters-Golden M., and Brock T.G. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 279 (2004) 41512-41520
124. Luo M., Jones S.M., Flamand N., Aronoff D.M., Peters-Golden M., and Brock T.G. Phosphorylation by protein kinase A inhibits nuclear import of 5-lipoxygenase. J Biol Chem 280 (2005) 40609-40616
125. Mancini J.A., Abramovitz M., Cox M.E., Wong E., Charleson S., Perrier H., et al. 5-Lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett 318 (1993) 277-281
126. Mancini J.A., Waterman H., and Riendeau D. Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein. J Biol Chem 273 (1998) 32842-32847
127. Matsuyama M., Yoshimura R., Mitsuhashi M., Tsuchida K., Takemoto Y., Kawahito Y., et al. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep 14 (2005) 73-79
128. 2+-ionophore A23187. Biochem J 280 (1991) 379-385
129. McGill K.A., and Busse W.W. Zileuton. Lancet 348 (1996) 519-524
130. McMillan R.M. Leukotrienes in respiratory disease. Paediatr Respir Rev 2 (2001) 238-244
131. McMillan R.M., and Walker E.R.H. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci 13 (1992) 323-330
132. Meghji S., Lillicrap M., Maguire M., Tabona P., Gaston J.S., Poole S., et al. Human chaperonin 60 (Hsp60) stimulates bone resorption: structure/function relationships. Bone 33 (2003) 419-425
133. Mehrabian M., Allayee H., Wong J., Shi W., Wang X.P., Shaposhnik Z., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circulation Res 91 (2002) 120-126
134. Mehrabian M., Allayee H., Stockton J., Lum P.Y., Drake T.A., Castellani L.W., et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 37 (2005) 1224-1233
135. Mellor E.A., Maekawa A., Austen K.F., and Boyce J.A. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci U S A 98 (2001) 7964-7969
136. Miller D.K., Gillard J.W., Vickers P.J., Sadowski S., Léveillé C., Mancini J.A., et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343 (1990) 278-281
137. Muro S., Hamid Q., Olivenstein R., Taha R., Rokach J., and Powell W.S. 5-oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin. J Allergy Clin Immunol 112 (2003) 768-774
138. Murphy R.C., Hammarström S., and Samuelsson B. Leukotriene C: a slow reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A 76 (1979) 4275-4279
139. Myers C.E., and Ghosh J. Lipoxygenase inhibition in prostate cancer. Eur Urol 35 (1999) 395-398
140. Nakano R., Oka M., Nakamura T., Fukuda M., Kawabata S., Terashi K., et al. A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein. Biochem Biophys Res Commun 251 (1998) 307-312
141. Neu I., Mallinger J., Wildfeuer A., and Mehlber L. Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand 86 (1992) 586-587
142. Nicolella D.N., Nicholls A.E., Bonewald L.F., and Lankford J. Mechanical properties of bone from mice lacking 5-lipoxygenase differ significantly from those of normal mice. Bone Miner Res 12 (1997) 157
143. Nielsen C.K., Campbell J.I., Ohd J.F., Morgelin M., Riesbeck K., Landberg G., et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 65 (2005) 732-742
144. Ohd J.F., Nielsen C.K., Campbell J., Landberg G., Lofberg H., and Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124 (2003) 57-70
145. Okuno T., Yokomizo T., Hori T., Miyano M., and Shimizu T. Leukotriene B4 receptor and the function of its helix 8. J Biol Chem 280 (2005) 32049-32052
146. Owman C., Nilsson C., and Lolait S.J. Cloning of cDNA encoding a putative chemoattractant receptor. Genomics 37 (1996) 187-194
147. Paredes Y., Massicotte F., Pelletier J.P., Martel-Pelletier J., Laufer S., and Lajeunesse D. Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis Rheum 46 (2002) 1804-1812
148. Paruchuri S., Broom O., Dib K., and Sjolander A. The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J Biol Chem 280 (2005) 13538-13544
149. Plante H., Picard S., Mancini J., and Borgeat P. 5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. Biochem J 393 (2006) 211-218
150. Powell W.S., and Rokach J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res 44 (2005) 154-183
151. Powell W.S., Zhang Y., and Gravel S. Effects of phorbol myristate acetate on the synthesis of 5-oxo-6,8,11,14-eicosatetraenoic acid by human polymorphonuclear leukocytes. Biochemistry 33 (1994) 3927-3933
152. Przylipiak A., Hafner J., Przylipiak J., Kohn F.M., Runnebaum B., and Rabe T. Influence of 5-lipoxygenase on in vitro growth of human mammary carcinoma cell line MCF-7. Gynecol Obstet Invest 46 (1998) 61-64
153. Qian C., Hwang S.B., Libertine-Garahan L., Eckman J.B., Cai X., Scannell R.T., et al. Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res 44 (2001) 213-220
154. Qiao L., Kozoni V., Tsioulias G.J., Koutsos M.I., Hanif R., Shiff S.J., et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1258 (1995) 215-223
155. Rådmark O. Arachidonate 5-lipoxygenase. J Lipid Mediat Cell 12 (1995) 171-184
156. Rådmark O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat 68-69 (2002) 211-234
157. Rask-Madsen J., Bukhave K., Laursen L.S., and Lauritsen K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions (1992) C37-C46 (Spec No)
158. Ren W., and Dziak R. Effects of leukotrienes on osteoblastic cell proliferation. Calcif Tissue Int 49 (1991) 197-201
159. Riddick C.A., Ring W.L., Baker J.R., Hodulik C.R., and Bigby T.D. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 246 (1997) 112-118
160. Rioux N., and Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 19 (1998) 1393-1400
161. Roberts W.G., Simon T.J., Berlin R.G., Haggitt R.C., Snyder E.S., Stenson W.F., et al. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 112 (1997) 725-732
162. Romano M., Catalano A., Nutini M., D'Urbano E., Crescenzi C., Claria J., et al. 5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 15 (2001) 2326-2336
163. Rossoni G., Sala A., Berti F., Testa T., Buccellati C., Molta C., et al. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Ther 276 (1996) 335-341
164. Rouzer C.A., Ford-Hutchinson A.W., Morton H.E., and Gillard J.W. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore challenged leukocytes. J Biol Chem 265 (1990) 1436-1442
165. Rouzer C.A., and Kargman S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J Biol Chem 263 (1988) 10980-10988
166. Samuelsson B., Dahlén S.-E., Lindgren J.-Å., Rouzer C.A., and Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 (1987) 1171-1176
167. Schröder O., Sjöström M., Qiu H., Stein J., Jakobsson P.J., and Haeggström J.Z. Molecular and catalytic properties of three rat leukotriene C(4) synthase homologs. Biochem Biophys Res Commun 312 (2003) 271-276
168. Serhan C. Lipoxins and aspirin-triggered 15-epi-lipoxins. In: Gallin J.L., and Syndermann R. (Eds). Inflammation Basic Principles and Clinical Correlates (1999), Lipincott Williams and Williams, Philadelphia
169. Sharon P., and Stenson W.F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86 (1984) 453-460
170. Shizawa T., Maeda K., Abe K., Ishii T., and Kamitani T. Effects of TMK688, a novel anti-allergic drug, on allergic nasal obstruction and exudative responses in sensitized guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 356 (1997) 815-819
171. Sjöström M., Johansson A.S., Schröder O., Qiu H., Palmblad J., and Haeggström J.Z. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) e37-e41
172. Spanbroek R., Stark H.J., Janßen-Timmen U., Kraft S., Hildner M., Andl T., et al. 5-Lipoxygenase expression in Langerhans cells of normal human epidermis. Proc Natl Acad Sci U S A 95 (1998) 663-668
173. Spanbroek R., Grabner R., Lotzer K., Hildner M., Urbach A., Ruhling K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 100 (2003) 1238-1243
174. Stamatiou P., Hamid Q., Taha R., Yu W., Issekutz T.B., Rokach J., et al. 5-oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats. J Clin Invest 102 (1998) 2165-2172
175. Steinhilber D. 5-Lipoxygenase: enzyme expression and regulation of activity. Pharm Acta Helv 69 (1994) 3-14
176. Steinhilber D. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr Med Chem 6 (1999) 69-83
177. Steinhilber D., Hoshiko S., Grunewald J., Rådmark O., and Samuelsson B. Serum factors regulate 5-lipoxygenase activity in maturating HL-60 cells. Biochim Biophys Acta 1178 (1993) 1-8
178. Straif D., Werz O., Kellner R., Bahr U., and Steinhilber D. Glutathione peroxidase-1 but not 4 is involved in the regulation of cellular 5-lipoxygenase activity in monocytic cells. Biochem J 349 (2000) 455-461
179. Subbarao K., Jala V.R., Mathis S., Suttles J., Zacharias W., Ahamed J., et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 369-375
180. Sundaram S., and Ghosh J. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem Biophys Res Commun 339 (2006) 93-98
181. Tager A.M., Dufour J.H., Goodarzi K., Bercury S.D., von Andrian U.H., and Luster A.D. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med 192 (2000) 439-446
182. Tateson J.E., Randall R.W., Reynolds C.H., Jackson W.P., Bhattacherjee P., Salmon J.A., et al. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol 94 (1988) 528-539
183. Tong W.G., Ding X.Z., Hennig R., Witt R.C., Standop J., Pour P.M., et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res 8 (2002) 3232-3242
184. Tong W.G., Ding X.Z., Witt R.C., and Adrian T.E. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1 (2002) 929-935
185. Tong W.G.D., Ding X.Z., and Adrian T. The leukotriene B4 receptor antagonist LY293111 induces S-phase arrest and apoptosis in human pancreatic cancer cells. Pancreas 25 (2002) 453
186. Tong W.G., Ding X.Z., Talamonti M.S., Bell R.H., and Adrian T.E. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 335 (2005) 949-956
187. Traianedes K., Dallas M.R., Garrett I.R., Mundy G.R., and Bonewald L.F. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology 139 (1998) 3178-3184
188. Tudhope S.R., Cuthbert N.J., Abram T.S., Jennings M.A., Maxey R.J., Thompson A.M., et al. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol 264 (1994) 317-323
189. Uhl J., Klan N., Rose M., Entian K.D., Werz O., and Steinhilber D. The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem 277 (2002) 4374-4379
190. Uozumi N., Kume K., Nagase T., Nakatani N., Ishii S., Tashiro F., et al. Role of cytosolic phospholipase A(2) in allergic response and parturition. Nature 390 (1997) 618-622
191. van de Kerkhof P.C., van Pelt H., Lucker G.P., Steijlen P.M., and Heremans A. Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. Skin Pharmacol 9 (1996) 307-311
192. Vickers P.J. 5-Lipoxygenase-activating protein (FLAP). J Lipid Mediat Cell Signal 12 (1995) 185-194
193. Vila L. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med Res Rev 24 (2004) 399-424
194. Wachtershauser A., Steinhilber D., Loitsch S.M., and Stein J. Expression of 5-lipoxygenase by human colorectal carcinoma Caco-2 cells during butyrate-induced cell differentiation. Biochem Biophys Res Commun 268 (2000) 778-783
195. Wedi B., and Kapp A. Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications. BioDrugs 15 (2001) 729-743
196. Weinblatt M.E., Kremer J.M., Coblyn J.S., Helfgott S., Maier A.L., Petrillo G., et al. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol 19 (1992) 1537-1541
197. Weitzel F., and Wendel A. Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone. J Biol Chem 268 (1993) 6288-6292
198. Werz O. 5-Lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 1 (2002) 23-44
199. Werz O., and Steinhilber D. Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells - the presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. Eur J Biochem 242 (1996) 90-97
200. Werz O., and Steinhilber D. Pharmacological intervention with 5-lipoxygenase: new insights and novel compounds. Expert Opin Ther Patents 15 (2005) 505-519
201. Werz O., Schneider N., Brungs M., Sailer E.R., Safayhi H., Ammon H.P.T., et al. A test system for leukotriene synthesis inhibitors based on the in-vitro differentiation of the human leukemic cell lines HL-60 and Mono Mac 6. Naunyn Schmiedebergs Arch Pharmacol 356 (1997) 441-445
202. Werz O., Szellas D., Henseler M., and Steinhilber D. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 54 (1998) 445-451
203. Werz O., Klemm J., Samuelsson B., and Rådmark O. 5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci U S A 97 (2000) 5261-5266
204. Werz O., Bürkert E., Fischer L., Szellas D., Dishart D., Samuelsson B., et al. Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. FASEB J 16 (2002) 1441-1443
205. Werz O., Bürkert E., Rådmark O., and Steinhilber D. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99 (2002) 1044-1052
206. Werz O., Szellas D., Steinhilber D., and Rådmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem 277 (2002) 14793-14800
207. Whitney L.W., Ludwin S.K., McFarland H.F., and Biddison W.E. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 121 (2001) 40-48
208. Woodmansee D.P., and Simon R.A. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 83 (1999) 548-552
209. Yokomizo T., Izumi T., Chang K., Takuwa Y., and Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387 (1997) 620-624
210. Yoo M.H., Song H., Woo C.H., Kim H., and Kim J.H. Role of the BLT2, a leukotriene B4 receptor, in Ras transformation. Oncogene 23 (2004) 9259-9268
211. Zhao L., Moos M.P., Grabner R., Pedrono F., Fan J., Kaiser B., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 (2004) 966-973
212. Zhi H., Zhang J., Hu G., Lu J., Wang X., Zhou C., et al. The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 106 (2003) 327-333
213. Zouboulis C.C., Nestoris S., Adler Y.D., Orth M., Orfanos C.E., Picardo M., et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 139 (2003) 668-670